news
Virtual method enables screening of billions of chemical compounds
A new platform, named Virtual Synthon Hierarchical Enumeration Screening, has been developed by researchers to efficiently discover drugs.
List view / Grid view
Parkinson's disease
article
Analysing proteomics data to translate in vivo studies as early as possible
Dr Antal Szalay, CEO and Founder of Ultimate Medicine, explores how the analysis of omics data, especially metabolomics and proteomics, can provide researchers with vital insight that can inform the development of drugs for conditions associated with age.
article
Highlights from Drug Target Review’s Cell & Gene Therapy Advancements Online Summit
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
news
New Oxford-GSK Institute aims to unravel complex diseases
GlaxoSmithKline (GSK) and the University of Oxford will collaborate to investigate diseases using technologies such as functional genomics and machine learning.
news
New compound may reduce erratic movements in Parkinson’s patients
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
news
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news
Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
news
$9 million grant awarded to uncover whether Parkinson’s starts in the nose
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
news
Mission Therapeutics receives $500k grant for Parkinson’s research
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
article
Determining the structure of nanobodies using nuclear magnetic resonance spectroscopy
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
news
Nasal drugs show promise for slowing Parkinson’s disease
Two different peptides were found to slow the spread of alpha-synuclein, potentially becoming the first drugs to slow the progression of Parkinson’s disease.
news
Multi-omics approach identifies genes associated with alcohol use disorder
First-of-its-kind study uses a multi-omics approach to provide a list of causal candidate genes associated with alcohol use disorder (AUD).
news
Mechanisms behind synapse degeneration in Alzheimer’s unveiled
Researchers have uncovered a signalling pathway associated with glutamatergic synapse degeneration in the brains of mice with Alzheimer’s.
news
New study discovers how Parkinson’s-linked protein attacks mitochondria
Researchers have used fruit fly larvae to explore how alpha-synuclein impacts the mitochondria, advancing the study of Parkinson’s disease.
news
TREM2 regulation to prevent neurodegeneration is possible, study shows
Scientists used a synthetic thyroid hormone in mice to regulate the TREM2 gene implicated in diseases such as Alzheimer’s and Parkinson’s.